Aclaris Therapeutics, Inc.

DB:8AT Stock Report

Market Cap: €258.5m

Aclaris Therapeutics Management

Management criteria checks 4/4

Aclaris Therapeutics' CEO is Neal Walker, appointed in Jul 2012, has a tenure of 12.5 years. directly owns 1.34% of the company’s shares, worth €3.46M. The average tenure of the management team and the board of directors is 2 years and 10.3 years respectively.

Key information

Neal Walker

Chief executive officer

US$73.5k

Total compensation

CEO salary percentagen/a
CEO tenure12.5yrs
CEO ownership1.3%
Management average tenure2yrs
Board average tenure10.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Neal Walker's remuneration changed compared to Aclaris Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$37m

Jun 30 2024n/an/a

-US$59m

Mar 31 2024n/an/a

-US$77m

Dec 31 2023US$74kn/a

-US$88m

Sep 30 2023n/an/a

-US$115m

Jun 30 2023n/an/a

-US$105m

Mar 31 2023n/an/a

-US$96m

Dec 31 2022US$6mUS$590k

-US$87m

Sep 30 2022n/an/a

-US$82m

Jun 30 2022n/an/a

-US$83m

Mar 31 2022n/an/a

-US$81m

Dec 31 2021US$7mUS$567k

-US$91m

Sep 30 2021n/an/a

-US$82m

Jun 30 2021n/an/a

-US$71m

Mar 31 2021n/an/a

-US$65m

Dec 31 2020US$2mUS$424k

-US$51m

Sep 30 2020n/an/a

-US$57m

Jun 30 2020n/an/a

-US$69m

Mar 31 2020n/an/a

-US$102m

Dec 31 2019US$3mUS$500k

-US$114m

Sep 30 2019n/an/a

-US$118m

Jun 30 2019n/an/a

-US$115m

Mar 31 2019n/an/a

-US$79m

Dec 31 2018US$4mUS$550k

-US$82m

Compensation vs Market: Neal's total compensation ($USD73.50K) is below average for companies of similar size in the German market ($USD898.34K).

Compensation vs Earnings: Neal's compensation has been consistent with company performance over the past year.

CEO

Neal Walker (54 yo)

12.5yrs

Tenure

US$73,500

Compensation

Dr. Neal S. Walker, D.O. & M.D., is Venture Partner of Forge Life Science Partners. He Co-founded Aclaris Therapeutics, Inc. in 2012 and has been its Director since July 2012 and serves as its Chairman sin...

Leadership Team

NamePositionTenureCompensationOwnership
Neal Walker
Co-Founder12.5yrsUS$73.50k1.34%
€ 3.5m
Kevin Balthaser
Chief Financial Officer2yrsUS$2.34m0.023%
€ 59.7k
Joseph Monahan
Chief Scientific Officer4yrsUS$2.26m0.16%
€ 415.6k
James Loerop
Chief Business Officer3yrsUS$2.33m0.032%
€ 82.2k
Hugh M. Davis
Presidentless than a yearno datano data
Matthew Rothman
General Counsel & Corporate Secretary2.6yrsno datano data
Jon Jacobsen
Senior Vice President of Chemistryno datano datano data
Steve Tucker
Senior Vice President of Project Leadershipless than a yearno datano data
Ajay Aggarwal
Senior Vice President of Clinical Developmentless than a yearno datano data
Steven Knapp
Executive Vice Presidentless than a yearno datano data

2.0yrs

Average Tenure

59yo

Average Age

Experienced Management: 8AT's management team is considered experienced (2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Neal Walker
Co-Founder12.5yrsUS$73.50k1.34%
€ 3.5m
Hugh M. Davis
Presidentless than a yearno datano data
Vincent Milano
Independent Director5yrsUS$180.38k0.012%
€ 30.3k
Mark Bradshaw
Member of Advisory Boardno datano datano data
James Leyden
Member of Advisory Boardno datano datano data
Klaus Theobald
Member of Advisory Boardno datano datano data
Anand Mehra
Independent Director10.3yrsUS$194.38k0.66%
€ 1.7m
Guy Webster
Member of Advisory Boardno datano datano data
Christopher Molineaux
Lead Independent Director11yrsUS$206.88k0.050%
€ 128.5k
Kenneth Beer
Member of Advisory Boardno datano datano data
Leslie Baumann
Member of Advisory Boardno datano datano data
Andrew Ondo
Member of Advisory Boardno datano datano data

10.3yrs

Average Tenure

62.5yo

Average Age

Experienced Board: 8AT's board of directors are seasoned and experienced ( 10.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 08:12
End of Day Share Price 2025/01/02 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Aclaris Therapeutics, Inc. is covered by 15 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Julian HarrisonBTIG
Louise ChenCantor Fitzgerald & Co.
Gavin Clark-GartnerEvercore ISI